Equities

Supriya Lifescience Ltd

SUPRIYA:NSI

Supriya Lifescience Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)648.30
  • Today's Change-9.90 / -1.50%
  • Shares traded291.04k
  • 1 Year change+163.91%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 10:20 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments7951,6402,339
Total Receivables, Net2,0151,5231,327
Total Inventory8521,158923
Prepaid expenses11210872
Other current assets, total204220313
Total current assets3,9784,6494,975
Property, plant & equipment, net4,5733,2812,317
Goodwill, net------
Intangibles, net171115
Long term investments6382530.53
Note receivable - long term----0
Other long term assets6.829.2840
Total assets9,2128,2037,348
LIABILITIES
Accounts payable596642490
Accrued expenses3.658.374.12
Notes payable/short-term debt0166213
Current portion long-term debt/capital leases4.683.548.25
Other current liabilities, total165137282
Total current liabilities769958997
Total long term debt505553
Total debt55225274
Deferred income tax232137111
Minority interest------
Other liabilities, total8.055929
Total liabilities1,0591,2081,191
SHAREHOLDERS EQUITY
Common stock161161161
Additional paid-in capital------
Retained earnings (accumulated deficit)7,9936,8345,996
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.01)(0.01)(0.01)
Total equity8,1546,9956,157
Total liabilities & shareholders' equity9,2128,2037,348
Total common shares outstanding808080
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.